Stray Dog

HIMS named as MAHA sponsor, peptide launch this year

  • Good news: A third party confirmed for the first time that HIMS is preparing to launch peptides this year, a high-margin line.
  • Bad news: Politico named HIMS as a sponsor paying for access to senior health officials, a new governance risk amid the FTC lawsuit.
  • Mixed: Branded GLP-1 volume has pushed gross margin down from 76% to 64%, which high-margin peptides could counter.
Read the full notes

A Politico report on 21 Sep named HIMS as one of the corporate sponsors of RFK's MAHA movement. It is also the first third-party confirmation that HIMS is preparing to launch peptide products this year. That is a key step:

Read more

the timeline for high-margin peptides moves from narrative to a concrete milestone, which would counter the core problem of branded GLP-1 volume pushing gross margin down from 76% to 64%. But it also exposes a double-edged bet on regulatory alignment and reputation. Paying for access to senior health officials during a sensitive compliance period (the FTC lawsuit of 29 Jul and the securities class action of 3 Sep) is itself a new governance risk. The core tension is unchanged: fast revenue growth (+38% year on year) against earnings quality and compliance costs eroding from both sides. The next proof point is still whether Q4 delivers a jump in profit. Risk/reward leans cautious.

Key evidence

  • Politico, 21 Sep: an RFK-linked non-profit raised money from companies in exchange for access to senior health officials. Bloomberg separately confirmed the group asked companies for about $300,000 for access to top health department officials at a summit.
  • The list of peptide sponsors names HIMS explicitly (alongside Noom and Wells Pharmacy) and says it is 'preparing to offer peptides later this year'. This is the first third-party confirmation.
  • In July the PCAC advisory committee recommended adding 6 of 7 peptides (including BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon) to the 503A compounding list. The decision rests with FDA/HHS (headed by RFK), and FDA has not yet formally adopted it.
  • The Q2 results on 10 Aug confirmed that branded GLP-1 volume pushed gross margin down from 76% to 64%. Peptides are the in-house, high-margin line that bulls value most.
  • A compliance overhang runs in parallel: the FTC lawsuit of 29 Jul and the securities class action filed on 3 Sep. They now stand in fresh contrast with HIMS actively moving closer to regulators.
  • SEC check: the latest 8-K is still the Q2 results of 10 Aug. The four Form 4 filings on 17-18 Sep are all pre-arranged 10b5-1 sales, and there are no new company announcements.

Catalysts to watch

  • Whether FDA/HHS formally adds the 6 PCAC-recommended peptides to the 503A compounding list. If it does, HIMS benefits from its head start.
  • An announcement from HIMS confirming the peptide launch this year, and the first SKUs
  • Whether the Q4 profit jump materialises (and management's timing on the high-margin peptide line)
  • How the public and regulatory backlash to the MAHA sponsorship story develops, and whether it triggers new compliance scrutiny or attention from Congress

Risks

  • The story of paying for access to senior health officials is a new reputational and governance risk during the sensitive compliance period around the FTC lawsuit and the class action
  • If the 6 peptides are not added to 503A, or are delayed, the bulls' core high-margin narrative loses its anchor
  • If the pressure that took gross margin from 76% to 64% widens further in Q3 or Q4, it would offset the peptide story
  • The MAHA link itself could invite regulatory backlash, or risk from a change in the political cycle

Sources 5

  1. Politico, 21 Sep: report on RFK/MAHA corporate sponsors
  2. Bloomberg: MAHA non-profit's $300,000 price for access
  3. HIMS Q2 results, 10 Aug (gross margin down from 76% to 64%)
  4. HIMS 8-K and Form 4 filings (17-18 Sep), SEC check
  5. FTC lawsuit of 29 Jul and securities class action filed on 3 Sep